An incurable virus that affects almost all Americans has been identified by scientists.
Researchers studying cancer at the University of Washington and the Fred Hutchinson Cancer Center in the United States created antibodies that stick to Epstein-Barr virus particles and prevent them from adhering to important immune cells.
One of those antibodies shielded mice with human-like immune systems from Epstein-Barr virus (EBV) infection, which is thought to afflict 95% of adult Americans.
One frequent virus in the herpes family is EBV. It is most well-known for producing infectious mononucleosis, sometimes referred to as “mono” or the “kissing disease.” The majority of people contract EBV at some point in their life, usually in childhood, with little to no symptoms.
Once contracted, the virus remains dormant in the body for the rest of one’s life, although it can occasionally reactivate, usually as a result of stress or a compromised immune system.
Symptoms like exhaustion or enlarged glands may occasionally result from it. Rarely, persistent or severe reactivation has been connected to some autoimmune conditions like lupus or multiple sclerosis, as well as some cancers like nasopharyngeal carcinoma or Hodgkin’s lymphoma, particularly in individuals with weakened immune systems.
The first virus found to cause cancer in humans was EBV. It is associated with over 209,000 deaths and 358,000 new cases of cancer annually.
“After many years of searching for a viable way to protect against Epstein-Barr virus, this is a significant stride for the scientific community and the people at the highest risk of complications from this virus,” stated biochemist and co-researcher Andrew McGuire.
Chronic fatigue, which can persist for weeks or months, is the defining sign of EBV. Additional symptoms include headache, enlarged spleen (stock), sore throat, and swollen lymph nodes in the neck and armpits.
Iframes are not supported by your browser.
The goal of the research was to create fully human antibodies that could prevent EBV infection, particularly in organ transplant recipients who are at high risk of contracting a fatal blood malignancy.
Instead of using mouse antibodies, the researchers employed genetically modified mice that made human antibodies.
After immunising the mice with two EBV surface proteins, they collected the antibody-producing mice’s cells and merged them with cancer cells to develop hybridomas, which are immortal cell lines that only produce one kind of antibody.
To identify antibodies that could prevent EBV from infecting B cells in lab dishes, they screened these antibodies.
Two antibodies against gp350 and eight against gp42 were found after the mice were immunised with the two EBV proteins, gp350 and gp42.
Compared to antibodies generated from mice, these antibodies may be safer for people because they are entirely human.
“Finding human antibodies that prevent Epstein-Barr virus from infecting our immune cells has been particularly challenging because, unlike other viruses, EBV finds a way to bind to nearly every one of our B cells,” McGuire stated.
By preventing the virus from attaching to a docking site on immune cells, the gp350 antibodies terminate the infection. A distinct docking site known as HLA class II is blocked by the gp42 antibodies.
Both strategies stop the virus from entering cells.
All of the animals were completely protected by the gp42 antibody, and the results showed that none of them had viruses in their spleens. Some mice continued to exhibit symptoms of infection, indicating that the gp350 antibody only provided partial protection.
Because of this, gp42 is a viable option for safeguarding high-risk individuals, such as organ transplant recipients who are susceptible to malignancies linked to EBV.
As of right now, there are no licensed EBV vaccines or targeted therapies. This finding offers promising prospects to move human trials forward, possibly closing that gap for the first time.
Those with compromised immune systems and patients of organ transplants are more susceptible to EBV-related malignancies.
Giving patients the gp42 antibody before they become ill could prevent EBV infection and prevent these tumours from growing, according to this discovery, which is described in Cell Reports Medicine.
The hundreds of thousands of people who have organ or bone marrow transplants each year potentially receive these antibodies. Transplant recipients are particularly vulnerable to EBV infection because they require medications that impair their immune systems.
On the other hand, if antibodies are able to prevent or lessen EBV infection at an early stage, the likelihood of acquiring EBV-related diseases in later life may be reduced.
